田文霞 赵玲 孟宪霞

    [摘要]肿瘤的发病率和病死率逐年升高，而现有的治疗手段有限。目前免疫卡控点抑制剂在多种肿瘤的治疗中广泛开展，免疫卡控点程序性死亡分子-1(PD-1)/PD-1配体(PD-L1)信号传导通路在肿瘤免疫抑制中发挥重要作用， PD-1/PD-L1通路可通过抑制免疫细胞活性和增强肿瘤细胞的免疫耐受，使肿瘤细胞发生免疫逃逸。近年来，针对 PD-1/PD-L1抑制剂的临床研究取得突破性进展。本文就 PD-1及其配体 PD-L1的生物学特性、作用机制及在多种肿瘤中的表达、免疫机制的研究进展做一综述，并对 PD-1/PD-L1在肿瘤治疗中的应用前景进行展望。

    [关键词] PD-1; PD-L1;肿瘤免疫;免疫抑制剂

    [中图分类号] R730.3? [文献标识码] A? [文章编号]2095-0616(2022)08-0064-04

    Advances in the study on the application of immune checkpoint PD-1/PD-L1 in tumor immunity

    TIAN? WenxiaZHAO? LingMENG? Xianxia

    1. Comprehensive Department， Jinan Health Promotion and Education Center， Shandong， Jinan 250000， China;2. Department of Rehabilitation Medicine， Jinan People’s Hospital， Shandong， Jinan 251199， China;3. Department of Clinical Laboratory， Blood Supply Guarantee Center ofJinan， Shandong， Jinan 250000， China

    [Abstract] The morbidity and mortality in individuals caused by tumors are increasing year by year but with limited available treatments. Currently， immune checkpoint inhibitors are being widely applied in the treatment of a variety of tumors. The immune checkpoint programmed death-1(PD-1)/PD-1 ligand (PD-L1) signaling pathway plays an important role in tumor immunosuppression ......